Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Montalescot, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Montalescot, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2007. For permissions please email: journals.permissions@oxfordjournals.org

Editorial

Gilles Montalescot*

Pitié-Salpêtrière, 47 Bl de l'Hôpital, Paris, France 75013

* Corresponding author. Tel: +33 1 42 16 30 07; fax: +33 1 42 16 29 31. E-mail address: gilles.montalescot@psl.ap-hop-paris.fr

The first 10% of the full text of this article appears below.

On 16 December 2006, a panel discussion was held in Roissy, France, that brought together leading experts on antiplatelet agents and the treatment of acute coronary syndromes (ACS) for a discussion on ‘Goals of Effective Platelet Inhibition’. Our purpose was to examine the results of recent clinical trials of antiplatelet agents so as to offer clinicians practical recommendations for their use in the . . . [Full Text of this Article]


   Conflict of interest:
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?